Technology tamfitronics
- News in Brief
- Published:
Nature Biotechnology volume42,page 824 (2024)Cite this article
Amgens T cell engager Imdelltra (tarlatamab) has gained FDA accelerated approval for an aggressive type of cell lung cancer that is notoriously difficult to treat.
The bispecific antibody is designed to bind both delta-like ligand 3 (DLL3) on small cell lung cancer (SCLC) cells and CD3 on T cells. Pharma companies have long considered DDL3 a promising target in oncology because healthy cells express it only in the cytoplasm, whereas 8596% of SCLCs express it at high levels on the tumor cell surface. By binding DDL3 on the one hand and CD3 on T cells on the other, the T cell engager brings the patients own immune cells and cancer cells into physical proximity, enabling the activated T cells to attack and kill DLL3-expressing cancer cells.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 /30days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
214,86 per year
only 17,91 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
First-in-class T cell engager approved for lung cancer. Nat Biotechnol 42824 (2024). https://doi.org/10.1038/s41587-024-02291-3
-
Published:
-
Issue Date:
-
DOI: https://doi.org/10.1038/s41587-024-02291-3